open access

Vol 56, No 2 (2022)
Letter to the Editors
Submitted: 2022-02-03
Accepted: 2022-02-03
Published online: 2022-02-15
Get Citation

Severity grading of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

James F. Meschia1
·
Pubmed: 35167116
·
Neurol Neurochir Pol 2022;56(2):193-194.
Affiliations
  1. Department of Neurology, Mayo Clinic, Jacksonville, Florida, United States

open access

Vol 56, No 2 (2022)
Letters to the Editors
Submitted: 2022-02-03
Accepted: 2022-02-03
Published online: 2022-02-15

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

.

About this article
Title

Severity grading of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 56, No 2 (2022)

Article type

Letter to the Editors

Pages

193-194

Published online

2022-02-15

Page views

4732

Article views/downloads

546

DOI

10.5603/PJNNS.a2022.0019

Pubmed

35167116

Bibliographic record

Neurol Neurochir Pol 2022;56(2):193-194.

Keywords

.

Authors

James F. Meschia

References (9)
  1. Meschia JF, Worrall BB, Rich SS. Genetic susceptibility to ischemic stroke. Nat Rev Neurol. 2011; 7(7): 369–378.
  2. Rutten JW, Dauwerse HG, Gravesteijn G, et al. Archetypal mutations frequent in public exome: implications for CADASIL. Ann Clin Transl Neurol. 2016; 3(11): 844–853.
  3. Antos A, Litwin T, Skowrońska M, et al. Pitfalls in diagnosing Wilson's Disease by genetic testing alone: the case of a 47-year-old woman with two pathogenic variants of the ATP7B gene. Neurol Neurochir Pol. 2020; 54(5): 478–480.
  4. Adib-Samii P, Brice G, Martin RJ, et al. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 2010; 41(4): 630–634.
  5. Rutten JW, Dauwerse HG, Peters DJM, et al. Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept. Brain. 2016; 139(Pt 4): 1123–1135.
  6. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004; 19(9): 1020–1028.
  7. Tan RY, Markus HS. CADASIL: Migraine, Encephalopathy, Stroke and Their Inter-Relationships. PLoS One. 2016; 11(6): e0157613.
  8. Opherk C, Peters N, Herzog J, et al. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004; 127(Pt 11): 2533–2539.
  9. Viswanathan A, Gschwendtner A, Guichard JP, et al. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL. Neurology. 2007; 69(2): 172–179.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl